Top insider buys and sells disclosed Friday

The article is a roundup of insider buying and selling across several US stocks, highlighting large purchases in Faeth Therapeutics, CarMax, Tortoise Energy Infrastructure, and Cross Timbers Royalty Trust, alongside major sales in Broadcom, Kymera Therapeutics, Oracle, Circle Internet Group, and Best Buy. The largest transaction was Broadcom director Henry Samueli’s $250.0 million sale of 694,241 shares, while CarMax director Mark F. O’Neil bought $502,656 of stock. Overall tone is informational rather than directional, with insider activity providing modest sentiment signals but no broad market implication.

Analysis

The tape is sending a split signal: management buying is concentrated in names where the market is already leaning bullish, while the biggest disposals are largely in stocks where liquidity and valuation have become the story. That matters because insider sales in a strong tape often cap upside only when they coincide with weak fundamentals; here, the more important read is that the market is willing to pay for growth/quality until a catalyst breaks the trend. The exception is the high-beta, narrative-driven names where insider selling can accelerate de-rating once momentum stalls.

KMX looks like the cleanest relative-value expression. Multiple insiders buying into strength suggests the used-car cycle may be bottoming faster than consensus expects, but the stock is no longer cheap enough to rely on mean reversion alone; the setup favors a tactical long only if wholesale trends and credit availability remain stable over the next 1-2 quarters. By contrast, CRCL’s insider sales reinforce that recent weakness is not just mechanical de-risking; in names where the market is already questioning growth durability, insider selling can trigger a second leg down as holders extrapolate slowing product monetization.

The larger opportunity is in pair construction around valuation dispersion, not outright directional bets. AVGO, KYMR, and ORCL sales all come from names with strong prior runs, which often means insider activity is more useful as a signal that upside is increasingly dependent on multiple expansion rather than earnings revision. The contrarian takeaway: BBY’s insider selling may be overread because the business still screens as a cash-yield compounder, while FATE and TYG buying is more likely to matter for sentiment than for near-term fundamentals given their smaller liquidity footprint.

Key Decisions for Investors

• Long KMX / short high-beta discretionary exposure for 4-8 weeks: insiders are leaning into strength, but use a tight stop if used-car/credit data rolls over; risk/reward favors a 1.5-2.0x upside capture versus downside if the cycle remains stable.
• Fade CRCL on rallies over the next 2-6 weeks: insider selling into a weak tape suggests any bounce is more likely short-covering than fundamental repair; consider put spreads to limit theta decay.
• Pair long BBY vs short CRCL for 1-3 months: BBY combines insider selling with a far better valuation/supportive yield backdrop, while CRCL still trades like a higher-multiple de-rating candidate.
• Avoid chasing AVGO and ORCL after the insider sales unless earnings revisions re-accelerate: use them as trim candidates on strength, not fresh longs, because upside now depends more on multiple expansion than fresh information.
• Speculative small-cap long FATE only on confirmation of continued volume and follow-through over 1-2 weeks; treat as momentum-only with a hard exit if liquidity weakens, since insider buying here is more sentiment support than fundamental proof.